TRIM63/IRF-8 Axis Promotes Tumor Progression and Immunosuppression of Melanoma with BRAF Mutation

Scientists demonstrated that TRIM63 exhibits overexpression in melanoma cells and exerts its full oncogenic potential upon activation of the MAPK signaling pathway. Mechanistically, BRAF mutation induces ERK1/2-mediated phosphorylation of TRIM63 at serine 69.